article thumbnail

STAT+: Under pressure to thwart pharma patent abuse, the PTO proposes a new rule. But will it fly?

STAT

Patent and Trademark Office has proposed a new rule designed to stem the use of so-called patent thickets , which are wielded by pharmaceutical companies to delay the arrival of lower-cost generic medicines in the marketplace. In a bid to prevent the patent system from being abused, the U.S.

article thumbnail

STAT+: U.S. Patent Office pulls controversial rule to curb pharma patent abuse

STAT

Patent & Trademark Office has withdrawn a controversial proposal that was designed to prevent pharmaceutical companies from abusing the patent system.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: FTC warns drugmakers they can face legal action over improper patent listings

STAT

The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly list patents for brand-name medicines in a Food and Drug Administration registry, the latest effort by the federal government to scrutinize patent moves by drugmakers.

article thumbnail

STAT+: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal

STAT

government to remove the key negotiator working on a free trade agreement with the Indian government because of his previous ties to a major pharmaceutical company. More than 200 civil society and patient advocacy groups are urging the U.K. Now, the groups are upset that the involvement of Harjinder Kang, the U.K.

article thumbnail

Union Budget 2025-26: A roadmap for India’s pharmaceutical leadership

Express Pharma

The Indian pharmaceutical sector is loaded with talent and has made great strides in generic medicine development. However, massive R&D expenditure is necessary to drive the next generation of discoveries.

article thumbnail

The rise of Fixed-Dose Combinations (FDCs): What it means for pharma players

Express Pharma

Additionally, pharmaceutical companies have increasingly turned to FDCs as a way to differentiate their products in a highly competitive market. By introducing unique formulations that combine existing drugs, companies can extend product life cycles and maintain exclusivity over certain combinations.

article thumbnail

Only 2 per cent medicines undergo quality control checks: Former IMA President

Express Pharma

Krishna Sarma, Managing Partner, Corporate Law Group , said, “The entanglement of Registered Medical Practitioners (RMPs) in third-party activities involving pharmaceutical companies, coupled with the haze surrounding generic medicines, beckons for clarity.